Literature DB >> 3026837

cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell.

T C Wun, K K Kretzmer.   

Abstract

The human hepatoma line Hep G2 produces an acid- and SDS-sensitive plasminogen activator inhibitor (PAI). This protein has been previously purified and used to raise polyclonal antibodies. This antiserum has been used to isolate cDNA clones from a human placental lambda gt11 cDNA library. The immunologically positive clones were screened for expression of recombinant proteins which inhibit urokinase activity and form an inhibitor-enzyme complex with 125I-urokinase. Two positives (lambda PAI 11.1 and lambda PAI 14.1) have been obtained. The cDNA insert of the longer isolate (lambda PAI 14.1) consists of 1962 base pairs encoding the entire mature Hep G2 PAI and a 3'-noncoding region of 801 base pairs. The clone apparently lacks portions of 5'- and 3'-untranslated sequences. The translated amino acid sequence matches the sequence obtained for the mature Hep G2 PAI and consists of 379 amino acids with a molecular mass of 42 770 Da. Interestingly, this PAI clone is quite different from the placental-type PAI-2 sequence as expected, but matches the sequence of the endothelial-type PAI (PAI-1) reported to be acid-insensitive and SDS-enhancible.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3026837     DOI: 10.1016/0014-5793(87)81288-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

Authors:  D E Vaughan; P J Declerck; M De Mol; D Collen
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

2.  Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.

Authors:  O F Wagner; C de Vries; C Hohmann; H Veerman; H Pannekoek
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 3.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

4.  TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway.

Authors:  B A Hocevar; T L Brown; P H Howe
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

5.  Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.

Authors:  H Zhang; T Morisaki; H Matsunaga; N Sato; A Uchiyama; K Hashizume; F Nagumo; J Tadano; M Katano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Species-specific differential cleavage and polyadenylation of plasminogen activator inhibitor type 1 hnRNA.

Authors:  P G Fattal; J J Billadello
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

7.  The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene.

Authors:  A Riccio; L R Lund; R Sartorio; A Lania; P A Andreasen; K Danø; F Blasi
Journal:  Nucleic Acids Res       Date:  1988-04-11       Impact factor: 16.971

Review 8.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

9.  Expression of calcium-binding protein S100A2 in breast lesions.

Authors:  D Liu; P S Rudland; D R Sibson; A Platt-Higgins; R Barraclough
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.